Mersana Therapeutics Inc
NASDAQ:MRSN
Mersana Therapeutics Inc
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. The company is headquartered in Cambridge, Massachusetts and currently employs 169 full-time employees. The company went IPO on 2017-06-28. The firm is focused on developing antibody drug conjugates (ADCs). The Company’s platforms include Dolaflexin and Dolasynthen. Its product candidates include upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592. The Company’s early stage programs include B7-H4-targeted Dolasynthen ADC, XMT-1660, as well as candidates leveraging the Immunosynthen platform. UpRi is an ADC utilizing the Company’s Dolaflexin platform and targeting NaPi2b, which is an antigen broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma. XMT-1592 uses the Company’s Dolasynthen platform and targets NaPi2b.
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. The company is headquartered in Cambridge, Massachusetts and currently employs 169 full-time employees. The company went IPO on 2017-06-28. The firm is focused on developing antibody drug conjugates (ADCs). The Company’s platforms include Dolaflexin and Dolasynthen. Its product candidates include upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592. The Company’s early stage programs include B7-H4-targeted Dolasynthen ADC, XMT-1660, as well as candidates leveraging the Immunosynthen platform. UpRi is an ADC utilizing the Company’s Dolaflexin platform and targeting NaPi2b, which is an antigen broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma. XMT-1592 uses the Company’s Dolasynthen platform and targets NaPi2b.
Clinical Progress: Mersana continued strong patient enrollment for the Emi-Le dose expansion cohorts, surpassing 45 patients, and is on track to share initial clinical data in the second half of 2025.
Emi-Le Efficacy: Intermediate doses of Emi-Le showed promising objective response rates, especially in B7-H4 high TNBC (29%) and ACC1 patients (56%).
Financial Position: The company ended Q2 2025 with $77 million in cash and expects its capital to last into mid-2026.
XMT-2056 Milestone: Mersana achieved a $15 million development milestone with GSK for its HER2-targeting ADC, with payment expected later this quarter.
Cost Controls: R&D and G&A expenses declined year-over-year due to lower headcount and reduced consulting fees, though restructuring charges impacted the quarter.
Pivotal Study Planning: Management is focused on designing future studies in post-topo-1 TNBC, with Fast Track designation potentially allowing a broader patient population.
Proteinuria Management: Protocol changes to mitigate proteinuria in Emi-Le expansion cohorts are in place, and upcoming data will clarify their effectiveness.
